Show All
ASX Building

Important Update to Shareholders: Share Consolidation Clarification

Share consolidation has commenced, and the temporary ASX ticker is MDCDA. DA is a deferred account used whilst the shares are being consolidated. Market opening 5th Aug 2022, expectations are consolidated shares will revert back to MDC

Blue test tubes synthetic

NanaBisTM - Now With Synthetic CBD and THC

Following the company’s transformation to a pureplay biotech, Medlab Clinical has focused on the development of key asset NanaBis, a 50:50 micellar formulation of CBD and THC, in the treatment of cancer-induced bone pain.

graphs and images showing investor data on a screen for stock market

Medlab proposes DUAL LISTING to the U.S. Nasdaq Stock Market

Medlab Clinical Ltd (ASX:MDC) welcomes all shareholders to exercise their voting rights at Extraordinary General Meeting scheduled for 28th July 2022.

Blue background with white digital symbols over it

Transforming into a pure-play biotech

With lead product NanaBis™ (NanoCelle® encapsulated 50:50 THC:CBD for pain) preparing to enter a Phase III trial in pain, management has decided to fully focus on therapeutics development and divested its nutraceuticals portfolio


Government grant to apply NanoCelle® to an RNA nasal vaccine

Medlab (ASX:MDC) receives Government grant to apply NanoCelle® to an RNA nasal vaccine in collaboration with University of NSW (UNSW) and Macquarie University (MQ) to fight COVID-19 future potential epidemics.

phone with a share graph on it

Global Investor News March 2022

Bimonthly Medlab news. This month: a note from our CEO, a research note from Morgan’s and UK NanaBis and NanoCBD.

Annual Message to Shareholders October 2021

Once Medlab Clinical’s listing on the ASX six years ago its experienced team of scientists have made extraordinary advances in the creation and manufacture of unique, world-leading products and valuable intellectual property.

Scientists with virtual reality glasses - Medlab Clincial

Medlab mixes reality with Microsoft

Read the three featured stories from Microsoft about Medlab's adoption of mixed reality solutions including HoloLens 2 head-mounted devices with Dynamics 365

woman in pain - Medlab Clinical

NanaBis demonstrates continued improvement in pain scores

The first cohort of Observational Study patients completing 12-month treatment with NanaBis™ demonstrated continued improvement in pain scores.

Scientists in Lab - Medlab Clinical

Medlab to be granted European patent for NanoCelle® drug delivery platform

European Patent Office issues Notice of Intention to grant Medlab Clinical patent for NanoCelle® drug delivery platform

Cheryl Maley - Medlab Clinical

Novartis’ Managing Director of Oncology (ANZ/NZ) joins Medlab Clinical board

Medlab Clinical appoints Novartis' Managing Director of Oncology for Australia and New Zealand as Non-Executive Director.

graphs and images showing investor data on a screen for stock market

Medlab Clinical raises $15 million and Leading Executive Joins Board

Medlab Clinical successfully raised $15 million via a two-tranche placement.